This site is intended for healthcare professionals
CDK 4/6 banner image
Implementing guideline recommendations for CDK4/6 inhibition in early breast cancer

EACCME®-accredited roundtable

Read time: 60 mins
Last updated:22nd Aug 2023
Published:22nd Aug 2023

Welcome to this EACCME®-accredited roundtable with Sara Tolaney, Hope S. Rugo and Marc Thill. Join the faculty as they review current clinical data and guidelines, discuss optimal CDK4/6 inhibitor use in early breast cancer (EBC) and explore treatment options in people at high risk of recurrence. Gain 1 CME credit by testing your knowledge of targeted therapies for EBC, watching the 60-minute roundtable and completing the final assessment.

Before watching the roundtable, please take a moment to evaluate your current level of knowledge on the topics covered by participating in this short quiz.

Please complete the following evaluation form

Thank you for completing the knowledge quiz!

Access the webinar here

1. What is currently the only approved CDK4/6 inhibitor for treating early breast cancer?
2. Approval of abemaciclib for use in people with high-risk HR+/HER2− early breast cancer was based on clinical trial data from which study?
3. What PARP inhibitor is recommended for people with early breast cancer, BRCA mutation and a high risk of recurrence?
4. How many patients with HR+/HER2– early breast cancer do you treat annually?

Roundtable agenda

Session Speaker
Introductions and overview Sara Tolaney, MD (Chair)
Advances with CDK4/6 inhibitors in the EBC treatment landscape Hope S. Rugo, MD
Exploring the safety and tolerability of CDK4/6 inhibitors in EBC Marc Thill, MD
Panel discussion: Optimal use of CDK4/6 inhibitors in EBC All faculty
Choosing the right treatment for EBC at high risk of recurrence Sara Tolaney, MD
Panel discussion: Choosing the right treatment for EBC at high risk of recurrence –
implementing guideline recommendations
All faculty
Q&A All faculty
Closing remarks Sara Tolaney, MD

Learning objectives

After participating in this educational activity, you will be able to:

  • Describe the role of CDK4/6 inhibitors within the treatment landscape for HR+/HER2– early breast cancer (EBC)
  • Identify differences in guideline recommendations for CDK4/6 inhibitor use in HR+/HER2– EBC
  • Assess patients at high risk of recurrence and select the optimal treatment
  • Recognise the current challenges for integrating CDK4/6 inhibitors approved for EBC into clinical practice


Professor Christopher Edwards.jpg

Sara Tolaney, MD, MPH (Chair)

Dr Sara Tolaney is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute and is internationally recognised for her research and education leadership in breast cancer. She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers, is a senior physician at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School.


Hope Rugo.pngHope S. Rugo, MD, FASCO

Dr Hope S. Rugo, MD, FASCO, is a medical oncologist specialising in breast cancer research and treatment. Dr. Rugo is the Director of Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center. She is a principal investigator of multiple clinical trials focusing on novel targeted therapeutics to improve the treatment of breast cancer, publishing widely in this area.


Professor Christopher Edwards.jpg

Marc Thill, MD, PhD

Professor Dr Marc Thill MD. PhD, is director of the Department of Gynecology and Gynecologic Oncology, spokesperson of the Interdisciplinary Breast Cancer Center and head of the Gynecologic Cancer Center at the Agaplesion Markus Hospital in Frankfurt am Main, Germany.



Sara Tolaney, MD, MPH – Grants/research support from AstraZeneca, Bristol-Myers Squibb, Cyclacel, Daiichi Sankyo, Eisai, Eli Lilly, Exelixis, Genentech/Roche, Gilead, Merck, Nanostring, Novartis, OncoPep, Pfizer, Sanofi and Seattle Genetics. Consultancy fees from 4D Pharm, Aadi Bioscience, ARC Therapeutics, Artios Biopharmaceuticals, Bayer, BeyondSpring Pharmaceuticals, Blueprint Medicines, CytomX, Incyte Corp, Menarini/Stemline, Myovant, OncXerna, Reveal Genomics, Umoja Biopharma, Zentalis Pharmaceuticals, Zetagen and Zymeworks.

Hope S. Rugo, MD, FASCO – Consultancy fees from for Daiichi Sankyo, Eisai, Mylan and Napo Pharmaceuticals. Grants/research support from Astellas Pharma Inc., AstraZeneca, Daiichi Sankyo, F. Hoffmann-La Roche AG/Genentech, Gilead Sciences, GlaxoSmithKline, Lilly, Merck & Co, Novartis, OBI Pharma, Pfizer, Pionyr Immunotherapeutics, Sermonix Pharmaceuticals, Stemline Therapeutics, Taiho Oncology and Veru.

Marc Thill, MD, PhD – Advisory board or panel fees from Agendia, Amgen, AstraZeneca, Aurikamed, Becton/Dickinson, Clearcut, Clovis, Daiichi Sankyo, Eisai, Exact Sciences, Gilead Science, Grünenthal (relationship terminated), GSK, Lilly, MSD, Neodynamics, Novartis, Onkowissen, Organon, Pfizer, pfm medical, Pierre-Fabre, Roche, RTI Surgical (relationship terminated), Seagen, Sirius Medical and Sysmex. Consultancy fees from Daiichi Sankyo, Lilly, Neodynamics, pfm medical. Grants/research support from AstraZeneca, Clearcut, Exact Sciences, Neodynamics, Novartis, pfm medical, Roche and RTI Surgical. Speakers’ bureau fees from Amgen, Art Tempi, AstraZeneca, Clovis (relationship terminated), Connect Medica, Eisai, Exact Sciences, Gilead Science, GSK, I-Med-Institute, Jorg Eickeler, Laborarztpraxis Walther et al., Lilly, Medscape, Medtronic (relationship terminated), MSD, Novartis, Onkowissen, Pfizer, pfm medical, Roche, Seagen, Sysmex, Viatris and Vifor Pharma. Other financial or material support from Amgen, AstraZeneca, Clearcut, Clovis (relationship terminated), Connect Medica, Daiichi Sankyo, Daiichi Sanyko, Eisai, Exact Sciences, Gilead, Hexal, Hexal, Lilly, MSD, Neodynamics, Neodynamics, Novartis, Novartis, Pfizer, Pfizer, pfm medical, pfm Medical, Roche, Roche, Roche, RTI Surgical, Seagen, Servier and Sirius Medical.